Enliven Therapeutics
- Market cap
- 3.03B
- P/E (TTM)i
- -25.07
- P/Bi
- 3.39
- EPSi
- -1.83
- Div yieldi
- 0.00%
- 52W posi
- 56%
Anonymous reader poll. Unscientific, not investment advice.
Enliven Therapeutics last traded at 41.36, down 2.43% on the session. The company carries a market value of roughly 3.03B, the #2416 most valuable US-listed company we track. Wall Street's 14-analyst consensus lands on Buy, with a price target averaging 73.67 (+78% from here). The shares sit 56% of the way up their 52-week range of 14.79 to 62.32.
✦ StockVane Quant Insights how this is computed
- Twelve-month momentum in the top 6% of the universe, above its 200-day average.
- Signal has read BUY for 6 months.
- Its last 4 Buy calls have averaged +3% over the following quarter.
- Recent price momentum is +43.4% on average (3-month/1-year).
- Main-fund capital flow has been a net outflow over the last 45 sessions.
- Short interest has risen to 11.8% of float.
- Analyst tilt is Buy.
- Price is below its 20-day average and below its 60-day average.
- The 20-day average is below the 60-day average, a short-term downtrend.
Computed by a StockVane algorithm from historical price, valuation and analyst data - not a person, not a forecast guarantee, and not investment advice.
Factor grades
Ranked against 977 U.S. stocks StockVane covers.
Valuation N/A
How expensive the stock is versus earnings, sales and its own 5-year history.
Not enough data to grade this factor.
Growth N/A
How fast revenue, profit and free cash flow are compounding.
Not enough data to grade this factor.
Profitability F
How much profit the business keeps from each dollar of sales and capital.
| Return on equity | -27.0% | Better than 5% |
| Return on invested capital | -31.1% | Better than 4% |
Momentum B-
Recent price strength, skipping the latest month to avoid short-term noise.
| 3-month return | -10.7% | Better than 26% |
| 6-month return | 5.4% | Better than 49% |
| 12-month return (ex latest month) | 192.2% | Better than 98% |
| Distance below 52-week high | 27.0% | Better than 33% |
Financial Health A+
Balance-sheet strength: leverage, liquidity and interest coverage.
| Current ratio | 28.7x | Better than 100% |
| Debt to assets | 0.1% | Better than 99% |
Analyst View A
What the Street thinks: share of Buy ratings and upside to the average target.
| Analysts rating Buy | 100.0% | Better than 80% |
| Upside to average target | 62.0% | Better than 88% |
Grades are relative rankings, not forecasts: A+ is the top 5% of the covered stocks on a factor, F the bottom 3%. Valuation is not adjusted for sector, so capital-light software tends to grade lower there than utilities. Recomputed every 6 hours from our market data. Not investment advice, and not tailored to your financial situation, goals, or risk tolerance.
Price chart
Performance
Key statistics
Price & volume
- Prev close
- 42.39
- Open
- 41.62
- Day range
- 41.04 - 42.38
- Avg price
- 41.47
- Volume
- 1.46M
- Turnover
- 60.60M
- Turnover ratei
- 2.41%
- Volume ratioi
- 1.21
- Amplitudei
- 3.16%
- 52-week rangei
- 14.79 - 62.32
Valuation
- P/Ei
- -22.60
- P/E (TTM)i
- -25.07
- P/Bi
- 3.39
- EPSi
- -1.83
- Book value / shi
- 12.22
- Net profit
- -134.09M
- Net assets
- 895.15M
Share structure
- Market cap
- 3.03B
- Float capi
- 2.50B
- Shares out
- 73.27M
- Float sharesi
- 60.52M
Dividend & listing
- Div yield (TTM)i
- 0.00%
- Dividend (TTM)
- 0.00
- Listing date
- 1970-01-01
33.6% below the 52-week high
Trading activity
Net capital flow main funds, last 45 sessions
-21.41M net over the window
Short interest
- Shares short
- 8.62M
- % of floati
- 11.77%
- Days to coveri
- 9.01
- As of
- 2026-09-15
Frequently asked questions
What is the current stock price of Enliven Therapeutics (ELVN)?
Enliven Therapeutics last traded at 41.36. The quote on this page refreshes every few seconds while US markets are open.
What is Enliven Therapeutics's market cap?
About 3.03B.
What is the P/E ratio of Enliven Therapeutics?
The trailing twelve-month P/E is -25.07. The Valuation tab shows it against the stock's own five-year range.
Does Enliven Therapeutics pay a dividend?
Enliven Therapeutics does not currently pay a regular dividend.
Is Enliven Therapeutics a buy according to analysts?
The consensus of 14 analysts is a Buy rating, with an average 12-month price target of 73.67, which implies 78.1% upside from the current price. This is not investment advice.
What is Enliven Therapeutics's StockVane Quant Rating?
The StockVane Momentum strategy currently rates Enliven Therapeutics a B (Buy). Twelve-month momentum in the top 6% of the universe, above its 200-day average. Not investment advice.
Quote time 2026-10-08 02:56:49 · For reference only, not investment advice and not tailored to your situation.